Clinical Trial Search

Primary: STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76) — 0; 133; 162; 122 Participants

Primary: Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat — 13; 3 Participants

Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…

Primary: Sputum Conversion — 36; 60; 36 percentage of participants

Primary: Change in log10 Colony Forming Units (CFU) Per (/) Milliliter (mL) of Direct Respiratory Sputum Samples From Baseline to Day 14 — -0.199; -0.017; -0.092; -0.092…

Primary: Number of Participants With Microbiologically Confirmed Tuberculosis Infection — 20 participants

Primary: Number of MDR TB Cases Amongst New TB Cases and Previously Treated TB Cases — 23; 64 Participants

Primary: Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC) — 0.98; 0.98; 0.96; 0.95 Percentage — p=<0.001

Primary: Number of Subjects With Solicited Local Symptoms — 20; 6; 1; 1 Subjects

Primary: Daily Decrease in log10 Transformed Colony-forming Unit (CFU) Counts Per ml Sputum From Baseline (Study Treatment Initiation) to Day 14 — 0.134; 0.096; 0.136; 0.119…

Primary: TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3…

Primary: Time to Culture Conversion — 5.6; 5.4; 5.5 weeks

Primary: Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time…

Primary: Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time…

Primary: Changes in TB Lesion Sizes Using High Resolution Computed Tomography (HRCT). — 8.11; 10.08; 6.64; 7.24 reader score

Primary: Number of Participants With Laboratory Test or Clinical Judgment Resulting in the Need to Stop Study Medication — 6; 3 participants — p=>.05

Primary: Cumulative Probability of Death or Unknown Vital Status by Week 24 — 5.2; 5.2 Cumulative probability per 100 persons — p=0.97

Primary: Notification Rate Ratio — 48.7; 30.5 notifications/100,000 persons/year — p=<0.01

Primary: Incident Rates of Definite Pulmonary Tuberculosis (TB) Disease, Not Associated With HIV-infection, Meeting the Case Definition 1 — 0.3; 0.6 cases per 100 person-years…

Primary: Feasibility: Participant Attendance — 10; 9; 7; 8 participants

Primary: Comparison of the Rate of Treatment Success at 18 Months (After Treatment Initiation) Between Arms B and C — 217; 121; 117; 5 Participants

Primary: Incidence of First Diagnosis of Active Tuberculosis, Death Related to Tuberculosis, or Death From Unknown Cause — 0.6506; 0.6736 Events per 100 person-years

Primary: The Time to Sputum Culture Conversion at Week 8 (Stage 1) — 51; NA Days — p=0.0034

Primary: Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time…

Primary: Percentage of Participants With Negative Lowenstein Jensen Cultures at Week 8 — 85; 94; 96 percentage of participants w/LJ cx con

Primary: Average Change Per Day (Slope) of Log Colony Forming Units (CFU) Counts From Day 0 to Day 14 (BACFU [0-14]) to Assess Bactericidal Activity — -0.039; -0.086; -0.065…

Primary: Cumulative Rate of Culture-Confirmed TB Disease in Participants ≥18 Years of Age AND Culture-Confirmed or Probable (Clinical) TB Disease in Participants Less Than [<]18…

Primary: Steady State Pharmacokinetic Exposure of RIF — 115.6988; 201.9725; 284.4278 Ratio

Primary: Early Bactericidal Activity (EBA) Measured as the Daily Rate of Change in log10 CFUs (Colony Forming Units) of M. Tuberculosis in Sputum on Solid Media (Days 0-14)…

Primary: Number of Healthy Participants Negative for Reaction at 24 Hours After Intradermal Injection With ESAT6-CFP10 — 13; 13; 14; 13 participants